Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 18, 2011, Pages 2817-2831

  Fornaro, Michele ^a   Aguglia, Eugenio ^a   Dell'Osso, Liliana ^a   Perugi, Giulio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Antidepressants; Bipolar disorder (BD); Bipolarity; Depression; Development; Major depressive disorder (MDD); Underestimation

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; 1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANAMINE; 11BETA (1,3 BENZODIOXOL 5 YL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; 3 (3,4 DICHLOROPHENYL) 2 (METHOXYMETHYL) 8 AZABICYCLO[3.2.1]OCTANE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; 6 (4 ETHYNYLPHENYL) 1,2,3,5,6,10B HEXAHYDROPYRROLO[2,1 A]ISOQUINOLINE; AGOMELATINE; AMIBEGRON; ANTIDEPRESSANT AGENT; CP 316311; CUTAMESINE; EMICERFONT; GSK 586529; JNJ 19567470; JNJ 792476; LU AA24530; LU AA34893; LU AA37096; MIFEPRISTONE; MONOAMINE; NELIVAPTAN; NS 2360; ONO 233M; ORG 26576; PEXACERFONT; SCH 900635; SSR 126374; SSR 411298; TESOFENSINE; TS 041; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERUCERFONT;

BIPOLAR DEPRESSION; DEPRESSION; DRUG MECHANISM; DRUG RESEARCH; DRUG USE; HUMAN; NONHUMAN; PRESCRIPTION; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 81855166091     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.632366     Document Type: Review

References (152)

1. Talmud. Tractate Derech Eretz Zuta, Chapter I. Available from: http://www.jewishvirtuallibrary.org/ jsource/Talmud/derecheretzruta1.html
2. Terra JL. Suicide risk and depression. Rev Prat 2008;12(4):385-8
3. Burcusa SL, Iacono WG. Risk for recurrence in depression.Clin Psychol Rev 2007;27(8):959-85
4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).JAMA 2003;289(23):3095-105
5. Salzer HM, Lurie ML. Anxiety and depressive states treated with isonicotinyl hydrazide (isoniazid).AMA Arch Neurol Psychiatry 1953;70(3):317-24
6. Scanlon WG, White WM. Iproniazid (marsilid): its use in office treatment of depression. Am J Psychiatry 1958;114(11):1036-7
7. Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride).Am J Psychiatry 1958;115(5):459-64
8. Healy D. The three faces of the antidepressants: a critical commentary on the clinical-economic context of diagnosis. J Nerv Ment Dis 1999;187(3):174-80
9. Poe TE. Fluoxetine. A new antidepressant. N C Med J 1988;49(7):391-2
10. Preskorn SH. CNS drug development. Part I: the early period of CNS drugs. J Psychiatr Pract 2010;16(5):334-9
11. Hanada K, Umemura S. Tricyclic antidepressants. Nippon Rinsho 2000;58(Suppl 2):633-7
12. Howland RH. MAOI antidepressant drugs. J Psychosoc Nurs Ment Health Serv 2006;44(6):9-12
13. Baghai TC, Volz HP, Moller HJ. Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 2006;7(4):198-222
14. Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 2004;65(Suppl 4):5-10
15. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001;3(1):22-7
16. APA. Diagnostic and Statistical Manual for Mental Disorders, Third Revision (DSM-III-R).A.P. Association; Washington, DC: 1980
17. APA. Diagnostic and Statistical Manual for Mental Disorders, Text Revision (DSM-IV-TR).4th edition. American Psychiatric Association; Washington, DC: 2000
18. Kennedy SH, Young AH, Blier P. Strategies to achieve clinical effectiveness: refining existing therapies and pursuing emerging targets. J Affect Disord 2011;132(Suppl 1):S21-8
19. Serretti A. Antidepressants, present and future. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(7):1531
20. Blier P. The well of novel antidepressants: running dry. J Psychiatry Neurosci 2010;35(4):219-20
21. Fornaro M, Giosue P. Current nosology of treatment resistant depression: a controversy resistant to revision. Clin Pract Epidemiol Ment Health 2010;6:20-4
22. Pacchiarotti I, Mazzarini L, Colom F, et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand 2009;120(6):429-40
23. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122(5):509-22
24. Coppen A, Shaw DM, Farrell JP. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1963;1(7272):79-81
25. McClure DJ. The role of dopamine in depression. Can Psychiatr Assoc J 1973;18(4):309012
26. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000;61(Suppl 6):4-6
27. Kicey CA. Catecholamines and depression: a physiological theory of depression. Am J Nurs 1974;74(11):2018-20
28. Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2007;21(5):461-71
29. Potter WZ, Manji HK. Catecholamines in depression: an update. Clin Chem 1994;40(2):279-87
30. Sulser F, Vetulani J, Mobley PL. Mode of action of antidepressant drugs. Biochem Pharmacol 1978;27(3):257-61
31. Wade A, Friis Andersen H. The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 2006;22(11):2101-10
32. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch Gen Psychiatry 1981;38(10):1160-80
33. Werner FM, Covenas R. Classical neurotransmitters and neuropeptides involved in major depression: a review. Int J Neurosci 2010;120(7):455-70
34. Wager-Smith K, Markou A. Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neurosci Biobehav Rev 2011;35(3):742-64
35. Wolkowitz OM, Reus VI. Neurotransmitters, neurosteroids and neurotrophins: new models of the pathophysiology and treatment of depression. World J Biol Psychiatry 2003;4(3):98-102
36. Baldwin DS. Where is the room for improvement in the drug treatment of depression and anxiety? Hum Psychopharmacol 2011;26(1):1-3
37. Nierenberg AA. Antidepressants: can't live with them, can't live without them. CNS Spectr 2010;15(3):146-7
38. Machado-Vieira R, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals 2010;3:19-41
39. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996;153(2):151-62
40. Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 2008;69(6):946-58
41. Payne JL, Quiroz JA, Zarate CA Jr, Manji HK. Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol Psychiatry 2002;52(10):921-6
42. Tome MB, Cloninger CR, Watson JP, Isaac MT. Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol. J Affect Disord 1997;44(2-3):101-9
43. KanedazA, Yasui-Furukori N, Nakagami T, et al. The influence of personality factors on paroxetine response time in patients with major depression. J Affect Disord 2011
44. Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs 2001;15(10):765-76
45. Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010;8(3):287-304
46. Catena-Dell'Osso M, Bellantuono C, Consoli G, et al. Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem 2011;18(2):245-55
47. Chopra K, Kumar B, Kuhad A. Pathobiological targets of depression. Expert Opin Ther Targets 2011;15(4):379-400
48. Gobbi G, Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides 2005;26(8):1383-93
49. Blier P, Gobbi G, Haddjeri N, et al. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci 2004;29(3):208-18
50. Mansvelder HD, Mertz M, Role LW. Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits. Semin Cell Dev Biol 2009;20(4):432-40
51. Lebowitz B, Harris HW. Drug discovery and mental illness. Dialogues Clin Neurosci 2002;4:325-8
52. Van Praag HM. State of the art. The impact of classification on psychopharmacology and biological psychiatry. Dialogues Clin Neurosci 2003;1:141-9
53. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
54. Bech P. Rating sales in depression: limitations and pitfalls. Dialogues Clin Neurosci 2006;8(2):207-15
55. Benazzi F. Various forms of depression. Dialogues Clin Neurosci 2006;8(2):151-61
56. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR.*D) study. Psychiatr Clin North Am 2003;26(2):457-94, x
57. Preskorn SH. Results of the STAR. *D study: implications for clinicians and drug developers. J Psychiatr Pract 2009;15(1):45-9
58. Trivedi RB, Nieuwsma JA, Williams JW Jr. Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. J Gen Intern Med 2011;26(6):643-50
59. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR. *D report. Am J Psychiatry 2006;163(9):1519-30; quiz 1665
60. O'Reardon JP. Pharmacologic and therapeutic strategies in treatment-resistant depression. Introduction and clinical presentations. CNS Spectr 2009;14(3 Suppl 4):4-6
61. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166(9):980-91
62. McElroy SL, Guerdjikova A, Mori N, Keck PE Jr. Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert Opin Investig Drugs 2010;19(12):1527-44
63. Tohen M, Case M, Trivedi MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry 2010;71(4):451-62
64. Mathews J, Garcia KS, Mintun MA, Sheline YI. Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study. Psychiatry Res 2006;146(2):149-55
65. Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord 2008;10(1 Pt 2):144-52
66. Perlis RH, Uher R, Ostacher M, et al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry 2011;68(4):351-60
67. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder STEP-BD).Biol Psychiatry 2003;53(11):1028-42
68. Ghaemi SN. Why antidepressants are not antidepressants: STEP-BD, STAR. *D, and the return of neurotic depression. Bipolar Disord 2008;10(8):957-68
69. Vazquez G, Tondo L, Baldessarini RJ. Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: a meta-analytic review. Pharmacopsychiatry 2011;44(1):21-6
70. Ghaemi SN, Rosenquist KJ, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004;161(1):163-5
71. Kora K, Kaplan P. Hypomania/mania induced by cessation of antidepressant drugs. Turk Psikiyatri Derg 2008;19(3):329-33
72. Rihmer Z, Gonda X. Antidepressant-resistant depression and antidepressant-associated suicidal behaviour: the role of underlying bipolarity. Depress Res Treat 2011;2011:906462
73. El-Mallakh RS, Ghaemi SN, Sagduyu K, et al. Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. J Affect Disord 2008;111(2-3):372-7
74. Rihmer Z, Akiskal H. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord 2006;94(1-3):3-13
75. Ghaemi SN, Ko JY, Goodwin FK. The bipolar spectrum and the antidepressant view of the world. J Psychiatr Pract 2001;7(5):287-97
76. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000;157(11):1873-5
77. Kiejna A, Rymaszewska J, Hadryś T, et al. Bipolar or unipolar? - the question for clinicians and researchers. J Affect Disord 2006;93(1-3):177-83
78. Angst J, Gamma A, Bowden CL, et al. Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM-IV major depressive episodes. Eur Arch Psychiatry Clin Neurosci 2011 Aug 5. [Epub ahead of print]
79. Angst J, Azorin JM, Bowden CL, et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch Gen Psychiatry 2011;68(8):791-8
80. Chun BJ, Dunner DL. A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. Bipolar Disord 2004;6(1):32-42
81. Akiskal HS, Mallya G. Criteria for the 'soft' bipolar spectrum: treatment implications. Psychopharmacol Bull 1987;23(1):68-73
82. Kaye NS. Is your depressed patient bipolar? J Am Board Fam Pract 2005;18(4):271-81
83. Perugi G, Akiskal HS, Lattanzi L, et al. The high prevalence of 'soft' bipolar (II) features in atypical depression. Compr Psychiatry 1998;39(2):63-71
84. Warden D, Rush AJ, Wisniewski SR, et al. What predicts attrition in second step medication treatments for depression?: a STAR. z.ast;D Report. Int J Neuropsychopharmacol 2009;12(4):459-73
85. Lucae S, et al. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol 2010;20(1):65-8
86. Perugi G, Fornaro M, Akiskal HS, et al. Are atypical depression, borderline personality disorder and bipolar II disorder overlapping manifestations of a common cyclothymic diathesis? World Psychiatry 2011;10(1):45-51
87. Ghaemi SN, et al. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord 1999;52(1-3):135-44
88. Posternak MA, Zimmerman M. How accurate are patients in reporting their antidepressant treatment history? J Affect Disord 2003;75(2):115-24
89. Perlis RH. Can single genes matter in a polygenic world? Biol Psychiatry 2010;68(9):783-4
90. Duffy A, et al. The implications of genetics studies of major mood disorders for clinical practice. J Clin Psychiatry 2000;61(9):630-7
91. Purcell SM, Wray NR, Stone JL, et al. International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460(7256):748-52
92. Perlis RH. Betting on biomarkers. Am J Psychiatry 2011;168(3):234-6
93. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004;29(10):1765-81
94. Zou YF, Ye DQ, Feng XL, et al. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 2010;20(8):535-44
95. Domschke K, Dannlowski U, Hohoff C, et al. Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol 2010;20(5):301-9
96. Keers R, Bonvicini C, Scassellati C, et al. Variation in GNB3 predicts response and adverse reactions to antidepressants. J Psychopharmacol 2011;25(7):867-74
97. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):593-602
98. Nierenberg AA. The perfect storm: CNS drug development in trouble. CNS Spectr 2010;15(5):282-3
99. Hirschfeld RM. Bipolar depression: the real challenge. Eur Neuropsychopharmacol 2004;14(Suppl 2):S83-8
100. Ghaemi SN, Ko JY, Goodwin FK. 'Cade's disease' and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002;47(2):125-34
101. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998;50(2-3):143-51
102. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64(1):53-9
103. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59(6):530-7
104. Kupfer DJ, Frank E, Grochocinski VJ, et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002;63(2):120-5
105. Sachs GS, Yan LJ, Swann AC, Allen MH. Integration of suicide prevention into outpatient management of bipolar disorder. J Clin Psychiatry 2001;62(Suppl 25):3-11
106. Meyer RE, Salzman C, Youngstrom EA, et al. Suicidality and risk of suicide-definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry 2010;71(8):e1-e21
107. Ghaemi SN. Toward a Hippocratic psychopharmacology. Can J Psychiatry 2008;53(3):189-96
108. Angst J, Marneros A. Bipolarity from ancient to modern times: conception, birth and rebirth. J Affect Disord 2001;67(1-3):3-19
109. Faravelli C, Gorini Amedei S, Scarpato MA, Faravelli L. Bipolar disorder: an impossible diagnosis. Clin Pract Epidemiol Ment Health 2009;5:13
110. Hirschfeld RM. Bipolar spectrum disorder: improving its recognition and diagnosis. J Clin Psychiatry 2001;62(Suppl 14):5-9
111. Fekadu A, et al. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord 2009;116(1-2):4-11
112. Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry 2003;53(8):640-8
113. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52(1):46-54
114. Schultz P. Are all antidepressants alike? Dialogues Clin Neurosci 1999;1(1):4-11
115. WHO. International Classifical of Diseases (ICD-10).10th edition. WHO; 1992
116. van Praag HM. Nosologomania: a disorder of psychiatry. World J Biol Psychiatry 2000;1(3):151-8
117. Kendler KS, Munoz RA, Murphy G. The development of the Feighner criteria: a historical perspective. Am J Psychiatry 2010;167(2):134-42
118. Akiskal HS. Validating 'hard' and 'soft' phenotypes within the bipolar spectrum: continuity or discontinuity? J Affect Disord 2003;73(1-2):1-5
119. Maremmani I, Perugi G, Pacini M, Akiskal HS. Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm. J Affect Disord 2006;93(1-3):1-12
120. Oedegaard KJ, Greenwood TA, Johansson S, et al. A genome-wide association study of bipolar disorder and comorbid migraine. Genes Brain Behav 2010;9(7):673-80
121. McElroy SL, Kotwal R, Keck PE Jr, Akiskal HS. Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? J Affect Disord 2005;86(2-3):107-27
122. Lucas MC, Weikert RJ, Carter DS, et al. Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain. Bioorg Med Chem Lett 2010;20(18):5559-66
123. Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: the next generation of antidepressants. Curr Neuropharmacol 2008;6(4):338-43
124. Stahl S. editor. Stahl's essential psychopharmacology. 3rd edition. Neuroscientific Basis and Practical Applications; Cambridge: San Diego: 2008
125. Kamiyama H, et al. Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medialprefrontal cortex pathway. Neuroscience 2011;177:159-69
126. Wulsin AC, Herman JP, Solomon MB. Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary- adrenocortical axis responsiveness to stress. Psychoneuroendocrinology 2010;35(7):1100-12
127. Breuer ME, et al. SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model. Naunyn Schmiedebergs Arch Pharmacol 2009;379(1):101-6
128. Davies J, et al. CPP, a new potent and selective NMDA antagonist. Depression of central neuron responses, affinity for [3H]D-AP5 binding sites on brain membranes and anticonvulsant activity. Brain Res 1986;382(1):169-73
129. Jordan GR, et al. Regionally selective and dose-dependent effects of the ampakines Org 26576 and Org 24448 on local cerebral glucose utilisation in the mouse as assessed by 14C-2-deoxyglucose autoradiography.Neuropharmacology 2005;49(2):254-64
130. Kalueff AV, Nutt DJ. Role of GABA in anxiety and depression. Depress Anxiety 2007;24(7):495-517
131. Borsook D, et al. GABA and circadian timekeeping: implications for manic-depression and sleep disorders. Med Hypotheses 1986;19(2):185-98
132. Nurnberg HG, Seidman SN, Gelenberg AJ, et al. Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology 2002;60(2 Suppl 2):58-66
133. Overstreet DH, Stemmelin J, Griebel G. Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacol Biochem Behav 2008;89(4):623-6
134. Stahl SM. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry 2008;69(11):1673-4
135. Naidu PS, Varvel SA, Ahn K, et al. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 2007;192(1):61-70
136. Chen CY, Tzeng NS, Chen YC. Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction. Gen Hosp Psychiatry 2010;32(6):647; e7-9
137. O'Donovan C, Garnham JS, Hajek T, Alda M. Antidepressant monotherapy in pre-bipolar depression; predictive value and inherent risk. J Affect Disord 2008;107(1-3):293-8
138. Gan Z, Diao F, Wei Q, et al. A predictive model for diagnosing bipolar disorder based on the clinical characteristics of major depressive episodes in Chinese population. J Affect Disord 2011
139. King M, et al. Development and validation of an international risk prediction algorithm for episodes of major depression in general practice attendees: the PredictD study. Arch Gen Psychiatry 2008;65(12):1368-76
140. Bondolfi G, Aubry JM, Golaz J, et al. A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study. Swiss Med Wkly 2006;136(5-6):78-85
141. Ricken R, Wiethoff K, Reinhold T, et al. Algorithm-guided treatment of depression reduces treatment costs - Results from the randomized controlled German Algorithm Project (GAPII).J Affect Disord 2011
142. Bauer M, et al. Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients wih depression. J Clin Psychopharmacol 2009;29(4):327-33
143. Trivedi MH, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004;61(7):669-80
144. Sheehan DV, Croft HA, Gossen ER, et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry (Edgmont) 2009;6(5):20-33
145. Pae CU. Desvenlafaxine: a new antidepressant or just another one? Expert Opin Pharmacother 2009;10(5):875-87
146. Adell A. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety. IDrugs 2010;13(12):900-10
147. Howland RH. Vilazodone: another novel atypical antidepressant drug. J Psychosoc Nurs Ment Health Serv 2011;49(3):19-22
148. Feiger AD, Heiser JF, Shrivastava RK, et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003;64(3):243-9
149. de Paulis T. Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression. Curr Opin Investig Drugs 2007;8(1):78-86
150. Bermack JE, Debonnel G. Effects of OPC-14523, a combined sigma and 5-HT1a ligand, on pre- and post-synaptic 5-HT1a receptors. J Psychopharmacol 2007;21(1):85-92. Epub 2006 Mar 13
151. Lifschytz T, Segman R, Shalom G, et al. Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr Drug Targets 2006;7(2):203-10
152. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354(12):1231-42